Summary Lonidamine is a substituted indazole carboxylic acid with a unique mechanism of action and early clinical studies have reported anti-tumour activity.
The indazole carboxylic acid derivative Lonidamine (1-[2,4-dichlorobenzyl]-l-H-indazole carboxylic acid), initially studied for its antispermatogenic properties, was found to have moderate anticancer activity in vivo against murine Lewis lung carcinoma and sarcoma 180 tumours (Silvestrini, 1981) . In vitro studies in experimental tumour systems indicate that Lonidamine inhibits oxygen consumption and aerobic glycolysis; an effect that is associated with marked ultrastructural mitochondrial changes (Floridi et al., 1981) .
In phase I studies of oral Lonidamine the most frequent side effects were myalgia, asthenia and somnolence (Weiss et al., 1985) . Myalgia was the dose limiting toxicity and occurred at a dose of 300-400 mg m-2 Weinerman et al., 1986) . Of particular interest was the complete lack of myelosuppression and alopecia. On the basis of these studies Lonidamine, 600 mg daily in divided doses, has been selected for phase II studies.
The pharmacokinetics of Lonidamine have been studied in preclinical models (Segre & Catanese, 1981) but there is relatively little pharmacokinetic data from patients (Young et al., 1981; Besner et al., 1984) . We have therefore measured Lonidamine levels using a high performance liquid chromatography assay (HPLC) with fluorescence detection in 17 patients after 1 month of therapy. In the present study, pharmacokinetic data have been analysed with respect to patient characteristics and Lonidamine side-effects.
The aetiology of Lonidamine induced myalgia is unknown.
In view of the effects of Lonidamine on mitochondria we have examined a small series of patients by in vivo 31P nuclear magnetic resonance spectroscopy (31P NMRS) to investigate a possible link between myalgia and high energy phosphate metabolism. 31P NMR has been successfully applied to the investigation of normal and diseased muscle metabolism (Cresshull et al., 1981; Radda 1986 ). Most patients with inherited mitochondrial myopathies demonstrate abnormal high energy phosphate metabolism at rest (Radda et al., 1985; Gadian et al., 1981; Eleff et al., 1984) and similar changes might therefore be expected in patients taking Lonidamine.
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Patients and methods

Patients
Between June 1988 and May 1989, 32 patients with histologically proven advanced breast cancer were entered into the study. Oral informed consent was obtained from all patients.
Patients were included provided they had measurable or evaluable disease, performance status 0-2 (Zubrod scale), age less than 75 years, no other previous or concomitant malignant tumours except for skin carcinoma or in situ cervical carcinoma, normal kidney function and no brain metastases. Osteolytic bone lesions were considered evaluable, but mixed or purely osteoblastic bone lesions and previously irradiated sites were considered inevaluable for response. Previous endocrine or chemotherapy was allowed but was stopped at least 1 month before. Fifteen patients had received endocrine therapy only whereas the remaining 16 patients had received both endocrine and chemotherapy. The number of different types of endocrine therapy and chemotherapy is shown in Table I . Haematological recovery (white blood count >3,500 mm-3, haemoglobin > lO g dl-', platelets > 100,000 mm-3) from the effects of previous treatment was mandatory. The median diseased-free interval from time of diagnosis to development of metastases was 35 months (range 2-212 months). Three patients had locally advanced disease only. Patient characteristics are shown in Table I (PCr) , and also of their low energy degradation product, inorganic phosphate (Pi). Nucleoside triphosphates produce three discrete The HPLC assay was based on that described by LeClaire et al., 1983 with modifications including the use of fluorescence detection and quantification by the use of external standards rather than an internal standard. The Lonidamine assay and its validation are described in detail elsewhere (Newell et al., 1991) . The logarithm of the plasma concentration of Lonidamine was plotted against time and the peak concentration following each dose was determined together with the time at which this occurred. In addition the lowest concentration during the 24 h study was recorded and, where an exponential decline in plasma levels was observed, the half-life calculated.
To investigate possible relationships between Lonidamine pharmacokinetics and patient characteristics (sex, age, performance status, prior treatment, liver metastases, urea, creatinine, liver enzymes (alanine transaminase, gamma glutamyl transaminase), albumin and total protein) and sideeffects (myalgia) at the time of sampling linear regression (continuous data) or one way analysis of variance (discontinuous data) studies were performed. Furthermore in two of the responding patients the pharmacokinetics were repeated, one at a time of progression.
Assessment of response and toxicity Patients were evaluable for response if they had received at least 1 month of treatment. Patients who received continuous steroids were not evaluable for response but evaluable for progressive disease. Objective responses were defined according to UICC criteria (Hayward et al., 1977) . A category for minor response was included where patients achieved greater than 25% but less than 50% reduction of the product of the two greatest perpendicular diameters of measurable lesions. Complete, partial and minor responses had to be sustained for at least 1 month and stable disease for at least 3 months. The duration of response is measured from the beginning of therapy to the date of disease progression.
Patients who received at least 1 week of treatment were evaluable for toxicity. Toxicity was graded on a scale of 0-4 (0 = absent, 1 = mild and transient, 2 = moderate, affecting daily activity although controlled symptomatically, 3 = marked, not responding to symptomatic treatment, requiring reduction of daily dose or stopping treatment, 4 =life-threatening).
Results
Response
Of the 32 patients entered into the study 28 were evaluable for response. Two patients died and one had evidence of progressive disease requiring chemotherapy before completing 4 weeks of treatment. One patient stopped treatment at 4 weeks because of general lethargy which was subsequently found to be unrelated to Lonidamine; she was considered inevaluable for response. The characteristics of responding patients are shown in Table II . Three of 28 (11%) patients achieved a partial response, 3 (11%) a minor response and 2 (7%) disease stabilisation (for 3 and 5 months). The estrogen receptor status of the primary tumour was not known for any of the responding patients. The remaining 20 patients developed progressive disease within 3 months of treatment.
Toxicity
The toxicity data are summarised in Table III . One of the patients who died had only received 4 days of Lonidamine and was inevaluable for toxicity; there was no evidence that this was treatment related.
The most frequent side-effect was myalgia. This occurred in 16 (53%) patients and was generally mild lasting for 1 to 4 weeks in the majority of patients. Two patients had grade 2 myalgia but this was self-limiting within 1 and 3 weeks. No patient required treatment with steroids. No patient required a dose reduction because of toxicity and 9 (30%) had no side-effects.
3'NMR spectroscopy Two of the four patients examined using 31P NMRS developed myalgia at rest whilst receiving Lonidamine. Contrary to expectation, the Pi/PCr and Pi/beta ATRP ratios tended to be lower on treatment than with pre-treatment values. The Pi/PCr ratio was reduced by 6% with no change in the Pi/beta ATP in the patient with grade 2 myalgia and 39% and 20% reductions respectively were observed in the patient with grade 1 myalgia. In one of the two asymptomatic patients the Pi/PCr and Pi/beta ATP ratios were reduced by 10% and 7% respectively and in the second the Pi became undetectable after starting Lonidamine (Table IV) .
The two symptomatic patients had pre-treatment resting muscle pHi values of 7.1 After starting Lonidamine this fell slightly to 7.0 in the patient with grade 1 myalgia. Of the two asymptomatic patients, the muscle pHi in the first was 7.0 and did not change on Lonidamine. The pre-treatment pHi was 7.1 in the second patient, but could not be measured on treatment because the Pi peak became undetectable.
Pharmacokinetics
The peak plasma levels of Lonidamine after the first 150 mg dose ranged from 7.6 to 3.8 iLg ml' (mean 15.5) and after the second from 5.3 to 33.3 gig ml-' (mean 15.8). The absolute range of the time at which the peaks were observed was 0.5 to 4.0 h (mean 1.9) for the first and 0.5 to 4.1 h (mean 2.0) for the second dose. The trough concentrations for the entire 24 h study period ranged from 1.7 to 10.8 pg ml-' (mean 5.1) and for the courses where an exponential decline in Lonidamine levels was observed the range of plasma half-lives was 2.5 to 7.8 h (mean 3.9). These data indicate that Lonidamine had been absorbed in all patients. Examples of plasma Lonidamine concentration vs time curves are shown in Figure 1 .
Increasing age was the only patient characteristic which related to Lonidamine pharmacokinetics. This was a weak positive linear correlation with peak concentration (r = 0.45, P = 0.02). The other patient characteristics, biochemistry and myalgia were unrelated to the pharmacokinetics of the drug.
Lonidamine pharmacokinetics were studied in three patients who responded to therapy. As shown in Figure la , the plasma levels in the responding patients were not clearly different from those who did not respond, three examples being given in Figure lb .
In addition to the major Lonidamine peak a number of other peaks were seen in HPLC chromatograms which were not detected in pre-treatment samples. The time course for the change in plasma levels of certain of these additional components parallel that of Lonidamine (Figure 2 ) and hence they are likely to be Lonidamine derived.
Discussion
This phase II study of Lonidamine in advanced breast cancer confirms other reports of activity in pre-treated patients. In a study by Band et al. (1986) 5 of 30 (17%) patients achieved a partial response, but three of these patients were given steroids to alleviate myalgia. Pronzato et al. (1989) have recently reported a response rate of 16% in 25 evaluable patients; no steroids were given in this study and it is therefore directly comparable to ours. Combining partial and minor responses together increases the response rate to 22%.
Toxicity was minimal and generally transient. In common with other studies myalgia was the most frequent side-effect Pronzato et al., 1989) . Although in vivo 31P NMRS has confirmed abnormal high energy phosphate metabolism in most patients with inherited mitochondrial myopathies at rest (Gadian et al., 1981) , in the present study similar techniques have failed to demonstrate abnormalities even though ultrastructural mitochondrial changes are known to occur in vitro (Floridi et al., 1981) . The reduction in both Pi/PCr and Pi/beta ATP ratios found in our patients has also been shown to occur in resting Wistar rat skeletal muscle (Griffiths, J., personal communication) . Furthermore, the magnitude of the changes observed does not appear to be related to the presence or absence of symptoms. To date we have no satisfactory explanation for these unpredicted findings. However, possible reasons for loss of intracellular Pi signal include drug induced cellular loss, an apparent fall resulting from sequestration of Pi into an NMR invisible pool, and broadening and flattening of the Pi peak due to pH heterogeneity (Madden et al., 1990) . However, in common with our results the resting pHi is frequently normal in patients with mitochondrial myopathy (Gadian et al., 1981) . Myalgia may, however, result from changes in extracellular pH which would not be detected by 31P NMRS. In this respect Lonidamine is known to stimulate lactate production by normal cells in vitro (Floridi et al., 1989) , an effect which would not be detected using the NMRS technique employed in this study. It must be noted, however, that this work is preliminary and more patients would be needed to confirm these hypotheses.
The pharmacokinetic data indicate that in all the patients studied there was absorption following oral administration. The peak and trough concentrations together with the halflife are in general agreement with previous investigations (Young et al., 1981; Besner et al., 1984) . Attempts to relate Lonidamine pharmacokinetics to either patient characteristics at the time of treatment or to side-effects revealed only one weak correlation. That is, the peak concentration tended to be higher in older patients. However, the small magnitude of this effect is such that it is unlikely to be of clinical significance.
No conclusions could be drawn on a possible correlation between tumour response and plasma concentrations, because of the small number of patients responding. Thus the present study does not confirm the suggestion of Besner et al. (1984) that the trough level of Lonidamine is lower (< 3 1tg ml-') in unresponsive patients than in responding individuals. In agreement with the present results, De Angelis et al. (1989) failed to detect any difference in Lonidamine plasma levels in patients with brain metastases who did or did not respond to the drug when given with radiotherapy.
The presence of a number of fluorescent components other than Lonidamine in the HPLC analyses of plasma from patients receiving the drug suggests that Lonidamine is metabolised. Thus the components were not present in pretreatment samples and the levels of certain of the components paralleled those of Lonidamine. Further experiments (Newell et al., 1991) have shown that in some patients the levels of Lonidamine increase after B-glucuronidase treatment further suggesting that at least one of the components may be a glucuronic acid conjugate of the parent compound (Figure 2 , relative retention volume = 0.8). The other components which are not sensitive to B-glucuronidase (Caldwell & Hutt, 1986 ) may represent amino acid conjugates of Lonidamine. It is possible that these components may be of clinical significance.
Lonidamine has a unique mechanism of action and spectrum of toxicity. In vitro studies suggest that it may inhibit recovery from potentially lethal damage from radiation and cytotoxic drugs. The place for Lonidamine in cancer therapy may therefore be in combination with cytotoxics or concomitant radiotherapy. Previous studies of Lonidamine in combination with chemotherapy in other tumour types such as non-small cell lung cancer (Breau et al., 1988) , malignant glioma (Carapella et al., 1985) , and bladder cancer (Giannotti et al., 1984) have not shown any potentiation of sideeffects. Moreover, when Adriamycin was given prior to Lonidamine in tumour bearing mice a synergistic antitumour effect was seen (Zupi et al., 1986) . Preliminary results using combination chemotherapy (5-fluorouracil, Adriamycin and cyclophosphamide) with and without Lonidamine has shown an increased response rate with the addition of Lonidamine (63% vs 44%, P = 0.002) and a longer median time to progression (39 weeks vs 25 weeks, P = 0.002) (Calabresi et al., 1990) . Thus Lonidamine in combination with chemotherapy may be a promising treatment option.
